GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...
West Pharmaceutical targets 2-3% organic sales growth for 2025, highlights GLP-1 market expansion
Q4 2024 Management View CEO Eric Green highlighted that the company achieved 3.3% organic revenue growth in Q4 2024, marking a return to quarterly growth. Notable drivers included strong performance ...
Palatin Technologies, Inc.: Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...
Veru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...